Tag: AI Drug Discovery
-
AI in Drug Discovery: Transforming Human Cognition and Decision-Making
The partnership between Iambic Therapeutics and AbbVie showcases how AI is transforming drug discovery, impacting cognitive processes and decision-making. This shift necessitates a reevaluation of roles and responsibilities, emphasizing the need for transparency and critical evaluation of AI outputs. Read more
-
AI-Driven Drug Discovery: Accelerating Therapeutic Innovation
AI-driven drug discovery is transforming pharmaceutical research by drastically reducing the time needed to design new therapies. This breakthrough holds the promise of more personalized medicines reaching the market faster, fundamentally altering the landscape of healthcare. Read more
-
AI-Driven Homodimer Predictions Accelerate Drug Discovery
DeepMind’s AlphaFold has expanded to include homodimer predictions, marking a significant advance in protein structure prediction. This development accelerates drug discovery by enabling precise modeling of complex protein interactions crucial for targeted therapeutics. Read more
-
AI and Biology: Transforming Drug Discovery to Precision Engineering
Vijay Pande’s VZVC is pioneering a shift in biology from discovery to engineering, driven by AI’s ability to design drugs with precision. This transformation promises to revolutionize drug discovery, though clinical trials remain a bottleneck. Read more
-
AI-Driven Co-Scientist Revolutionizes Experimental Design
Co-Scientist, an AI platform, is transforming experimental design by analyzing complex data to suggest novel scientific hypotheses. This advancement could accelerate drug discovery and other research fields, leading to faster scientific breakthroughs. Read more
-
AlphaFold’s Homodimer Predictions: A Leap in Drug Discovery
The expansion of AlphaFold to include homodimer predictions significantly enhances drug discovery processes. By providing precise models of protein interactions, it opens new avenues for targeted therapies. Read more
-
Agentic AI Enters the Drug Discovery Lab Bench
Ono Pharmaceutical is embedding Phylo’s Biomni Lab agentic AI platform across its discovery science teams, tasking AI agents with synthesizing internal experimental history, framing hypotheses, and designing experiments in real time alongside scientists. The move reflects a specific theory about where drug discovery loses time — not in individual experiments, but in the cognitive overhead… Read more
-
AI-Directed Robotic Labs Are Rewriting Antibody Development Timelines
MegaRobo’s Megalaxy Laboratory in Suzhou completed 56 rounds of antibody optimization experiments in four months using eight researchers, reporting prediction accuracy gains from 70 to 90 percent across stability, expression, toxicity, and binding affinity. The system’s closed-loop architecture — AI agents directing robotic hardware and updating experimental choices from real wet-lab results — represents a… Read more
-
Cytosurge’s FluidFM®: Pioneering Causal Data in AI Drug Discovery
Cytosurge’s FluidFM® technology is pioneering causal data collection in AI drug discovery, enabling precise analysis of living cells. This advancement could significantly improve drug target identification and reduce failure rates in clinical trials. Read more
-
AI Models Enable Breakthroughs in Drug Repurposing Strategies
Miles Wang, an OpenAI researcher, is launching a startup focused on leveraging AI to repurpose existing drugs, potentially accelerating drug discovery and reducing costs. This approach utilizes AI models to analyze complex datasets for novel therapeutic applications, paving the way for faster, more efficient drug development. Read more
